Home › NDC Lookup › RxCUI directory › RxCUI 2289413

5.5 ML romidepsin 5 MG/ML Injection — RxCUI 2289413

RxNorm drug concept · Semantic clinical drug
RxCUI 2289413 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2289413
Official name5.5 ML romidepsin 5 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asromidepsin 27.5 MG per 5.5 ML Injection; romiDEPsin 27.5 MG in 5.5 ML Injection; romidepsin 5 MG/ML per 5.5 ML Injection
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Romidepsin Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Romidepsin is used to treat a type of skin cancer called cutaneous T-cell lymphoma, or CTCL. It's specifically for adults who have already tried at least one other systemic treatme...
  • The most common things people notice are nausea, fatigue, loss of appetite, and changes in taste. Low blood counts are also very common — your team will check your blood regularly....
  • What side effects should I expect, and which ones should I call my doctor about right away?
  • Yes — a few important ones. Rifampin (used for tuberculosis) should be avoided entirely. Certain antifungals and other drugs that affect a liver enzyme called CYP3A4 can increase r...
📖 Read our full Romidepsin Injection guide →

🕸️ Concept Web — How 5.5 ML romidepsin 5 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 5.5 ML romidepsin 5 MG/ML Injection RxCUI 2289413

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Romidepsin 877510
  2. Dose forms 4

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Romidepsin Injection 1724267
    • Romidepsin Injectable Product 1157980
    • Injection 1649574
    • Injectable Product 1151126
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Romidepsin 5 MG/ML 2289410

Showing up to 8 concepts per family — 6 of 6 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Romidepsin 5 MG/ML SCDC · 2289410
  • Romidepsin Injection SCDF · 1724267
  • Romidepsin Injectable Product SCDG · 1157980

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2289413 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70121-2250-01 1 VIAL in 1 CARTON (70121-2250-1) / 5.5 mL in 1 VIAL ROMIDEPSIN Amneal Pharmaceuticals LLC 2026-06-02
Observed labelers: Amneal Pharmaceuticals LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.